EGIS Pharmaceuticals PLC

[On Demand]
The PREDYSTIC® Infliximab RA Kit is a first-in-class, CE IVD labelled, molecular biomarker diagnostic system, suitable for predicting infliximab responsiveness in rheumatoid arthritis patients, before the first biological treatment initiation. This novel tool supports the decision making of stakeholders including rheumatologists, patients, payors, and drug developers.

Egis (member of the Servier Group) headquartered in Budapest, Hungary, is one of the leading generic pharmaceutical companies in Central and Eastern Europe. The company’s activities extend to every field of the pharmaceutical value chain: from Research and Development through the production of Active Pharmaceutical Ingredients and Finished Drug Products to sales and marketing. Egis products are available in 60 countries through its network of subsidiaries and representative offices or partners. Egis launched the first biosimilar infliximab for the treatment of rheumatoid arthritis in Central and Eastern Europe in 201
Company Type:
Privately Funded Company
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
PREDYSTIC Infliximab RA diagnostic test
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
International licence-out manager
EGIS Pharmaceuticals